| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health |
| Ongoing | 4 | 136 | Europe | Tablet, Xifaxan | Aleksander Krag, Dep. Gastroenterology Odense Universityhospital, Novo Nordisk fundation center for basic metabolic research | Liver fibrosis, Accumulation of scar tissue in the liver (fibrosis) may lead to the levelopment of liver cirrhosis. Liver cirrhosis is associated with a variety of complications and decreased survival., Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy |
|
|
| Terminated | 4 | 6 | US | Placebo, Rifaximin, XIFAXAN® Tablets | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 02/16 | 02/16 | | |
2016-002628-96: Does Rifaximin reduce the risk of infection for patients admitted to hospital with liver disease? |
|
|
| Ongoing | 4 | 268 | Europe | TARGAXAN, Film-coated tablet, TARGAXAN | Imperial College London, Norgine BV, Alfa Wassermann | Decompensated cirrhosis - liver disease, Liver disease, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
ChiCTR-OPC-15007624: The effects of rifaximin on the gut flora of diarrhea-dominated irritable bowel syndrome |
|
|
| Recruiting | 4 | 75 | | rifaximin ;rifaximin ;rifaximin ;rifaximin ;Pinaverium bromide | Union Hospital, Tongji Medical College, Huazhong University of Science & Technology; Union Hospital, Tongji Medical Collage, Huazhong University of Science and Technology, Key project of national nature fundation (02.07.13020116) | irritable bowel syndrome | | | | |
2016-004159-56: Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment of symptomatic uncomplicated diverticular disease of colon Appropriatezza d¿uso di Mesalazina e/o di Rifaximina nel trattamento della malattia diverticolare sintomatica non complicata del colon |
|
|
| Ongoing | 4 | 820 | Europe | Rifaximina, mesalazina, Rifaximina, mesalazina, Tablet, NORMIX - 200 MG COMPRESSE RIVESTITE CON FILM 12 COMPRESSE, ASACOL - 800 MG COMPRESSE GASTRORESISTENTI 60 COMPRESSE | DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II, AIFA - Italian Medicines Agency | Treatment of symptomatic uncomplicated diverticular colon disease (SUDD) trattamento della malattia diverticolite sintomatica non complicata del colon (SUDD), Treatment of symptomatic uncomplicated diverticular colon disease (SUDD) trattamento della malattia diverticolite sintomatica non complicata del colon (SUDD), Diseases [C] - Digestive System Diseases [C06] | | | | |
2018-004323-37: Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt: a multi-centre randomized, double blind, placebo controlled trial. The PEARL trial |
|
|
| Not yet recruiting | 4 | 238 | Europe | Xifaxan, Lactulose, Tablet, Syrup, Xifaxan, Lactulose | Academic Medical Centre, Academic Medical Centre, ZonMw, Norgine B.V. | post-TIPS Hepatic Encephalopathy (HE), Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt placement, Diseases [C] - Symptoms and general pathology [C23] | | | | |
2019-002116-10: Post-autorization study to compare the eficacy of the food supplement i3.1 and the antibiotic Rifaximin on SIBO (Small Intestinal Bacterial Overgrowth) reduction in patients suffering IBS (Irritable bowel syndrom). Estudio post-autorización para comparar la eficacia del complemento alimenticio i3.1 y el antibiótico Rifaximina en la reducción de SIBO (Sobrecrecimiento bacteriano en intestino delgado) en pacientes que padecen IBS (Síndrome intestino irritable). |
|
|
| Ongoing | 4 | 46 | Europe | SPIRAXIN, 62.250, Tablet, SPIRAXIN | AB-Biotics S.A., AB-Biotics S.A. | Irritable Bowel Syndrome (IBS) + Small Intestinal Bacterial Overgrowth (SIBO) Síndrome Intestino Irritable (SII) + Sobrecrecimiento bacteriano intestinal (SIBO), Irritable Bowel Syndrome (IBS) + Small Intestinal Bacterial Overgrowth (SIBO) Síndrome Intestino Irritable (SII) + Sobrecrecimiento bacteriano intestinal (SIBO), Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
NCT03818672: Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects |
|
|
| Terminated | 4 | 5 | US | Rifaximin | Bausch Health Americas, Inc. | Severe Hepatic Impairment | 02/20 | 02/20 | | |
ChiCTR1900022234: Effects of Long-term Prophylactic Use of Rifaximin-α on Intestinal Microbial Composition and Resistome in Patients with Liver Cirrhosis |
|
|
| Recruiting | 4 | 20 | | takel the Rifaximin-α | the First Affiliated Hospital, Zhejiang University; the First Affiliated Hospital, Zhejiang University, The study is sponsored by State Key Laboratory for Diagnosis & Treatment of Infectious Diseases and AW (China) | Liver Cirrhosis | | | | |
NCT04674176: Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet |
|
|
| Not yet recruiting | 4 | 30 | US | Rifaximin | Bayhealth Medical Center | Weight Loss | 01/22 | 01/22 | | |
NCT04074421: Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D |
|
|
| Recruiting | 4 | 240 | RoW | Rifaximin, Probiotic Formula, probiotic formula Bacillus subtilis and Enterococcus faecium, Placebo oral tablet, Placebo | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sir Run Run Shaw Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, RenJi Hospital, Peking Union Medical College Hospital, First Affiliated Hospital of Wenzhou Medical University, The Central Hospital of Lishui City | IBS - Irritable Bowel Syndrome, Gut Microbiota | 06/22 | 12/22 | | |
PEARL, NCT04073290: Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose |
|
|
| Recruiting | 4 | 238 | Europe | Rifaximin 550 milligram Oral Tablet [XIFAXAN], TARGAXAN, Placebo oral tablet, Placebo, Lactulose 667 milligram/milliliter Oral Solution, Lactulose syrup | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Leiden University Medical Center, Maastricht University Medical Center, Radboud University Medical Center, University Medical Center Groningen, Universitaire Ziekenhuizen Leuven, Norgine | Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension, Liver Diseases, Pathological Processes | 09/22 | 09/23 | | |
NCT05083572: Effect of Probiotic on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers |
|
|
| Recruiting | 4 | 32 | RoW | Colonic lavage with polyethylene glycol, PEG, Probiotic, Vivomixx, Antibiotic, Rifaximin | Changi General Hospital | Dysbiosis | 11/22 | 11/22 | | |
NCT05867550: To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea |
|
|
| Completed | 4 | 162 | RoW | Rifaximin 550 MG, Rifaxa 550MG, Nimixa 550 MG, Xifaxa 550MG, Zerifax 550MG, Nixaf 550 MG, Mebeverine 135 MG, Colofac 135 MG, Spasler Neo 135 MG, Mebever 135 MG, Psyllium Husk, Ispaghol, Amitriptyline Hydrochloride 25 MG, Tryptanol 25 MG | Bahria University | Irritable Bowel Syndrome With Diarrhea | 03/23 | 06/23 | | |
ChiCTR2100046116: Efficacy of lifestyle intervention and rifaximin for metabolic associated fatty liver disease |
|
|
| Recruiting | 4 | 34 | | rifaximin ;placebo | Xiangya Hospital of Central South University; Xiangya Hospital of Central South University, key research and development program of Hunan province (2020SK2068) | metabolic associated fatty liver disease, MAFLD | | | | |
NCT03219528: A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing |
|
|
| Completed | 4 | 64 | US | Rifaximin 550 MG, Low FODMAP Diet | University of Michigan, Michigan Institute for Clinical and Health Research (MICHR) | Irritable Bowel Syndrome | 02/24 | 02/24 | | |
NCT03729271: Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea |
|
|
| Recruiting | 4 | 110 | US | Rifaximin, Xifaxan, Glucose and lactulose hydrogen breath testing | University of Michigan, Commonwealth Diagnostics International, Inc. | Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea | 01/25 | 01/25 | | |
| Recruiting | 4 | 100 | RoW | Rifaximin, Low FODMAP diet | University of Malaya | Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth | 05/24 | 05/24 | | |
ChiCTR2300069313: Effect and mechanism of combined proton pump inhibitors and rifaximin treatment in functional dyspepsia patients |
|
|
| Not yet recruiting | 4 | 96 | | Rifaximin 1200 mg given at 400 mg three times per day for 2 weeks; Rabeprazole 10mg once daily for 4 weeks ;Rabeprazole 10mg once daily for 4 weeks | Gastroenterology Department of Peking University Third Hospital; Peking University Third Hospital, National Key Research and Development Program of China (No. 2019YFA0905600) | Functional Dyspepsia | | | | |
NCT06312683: Rifaximin for the Secondary Prevention of Recurrent Pouchitis |
|
|
| Recruiting | 4 | 16 | US | Rifaximin 550 MG Oral Tablet [XIFAXAN], Xifaxan | University of North Carolina, Chapel Hill, Bausch Health Americas, Inc. | Pouchitis | 07/26 | 07/26 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 06/25 | 09/25 | | |
ARGO-HEC, ChiCTR2300075925: Assessment of reversal in grades of overt hepatic encephalopathy by comparing the efficacy of rifaximin, probiotic and L-ornithine- L aspartate with lactulose as control drug for clinical trial. |
|
|
| Not yet recruiting | 4 | 240 | | LACTULOSE; RIFAXIMIN + LACTULOSE; PROBIOTIC + LACTULOSE; (L-Ornithine L- Aspartate) LOLA + LACTULOSE | The Islamia University of Bahawalpur; The Islamia University of Bahawalpur (IUB), self | Hepatic Encephalopathy | | | | |
ChiCTR2400082111: Modulation of intestinal microecology by rifaximin in patients with irritable bowel syndrome - a single-center, prospective, open-label clinical study |
|
|
| Not yet recruiting | 4 | 100 | | oral administration of rifaximin; None (samples from subjects before treatment) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-financing | irritable bowel syndrome | | | | |
ChiCTR2200067252: Rifaximin for Preventing Complications in Patients with Decompensated Liver Cirrhosis: a Multi-center Randomized Prospective Study |
|
|
| Not yet recruiting | 4 | 150 | | conventional therapy ;rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks ;rifaximin 1200mg/d (600mg, bid) for 24 weeks | Shanghai East Hospital, Tongji University School of Medicine; Shanghai East Hospital, Tongji University School of Medicine, Joint Research Project of Pudong New Area Health Commission, Clinical Research Project of Dongfang Hospital | liver cirrhosis | | | | |
| Ongoing | 3 | 120 | Europe | PENTACOL 800*60CPR 800MG R.M., NORMIX*AD 12CPR RIV 200MG, PENTACOL 800*60CPR 800MG R.M., NORMIX*AD 12CPR RIV 200MG | SOFAR SPA | not applicable | | | | |
2017-000488-34: Role of rifaximin in decreasing the circulating levels of endotoxin in patients with cirrhosis Ruolo della rifaximina per ridurre gli alti livelli sanguigni di endotossina nei pazienti affetti da cirrosi epatica |
|
|
| Not yet recruiting | 3 | 40 | Europe | RIFAXIMINA, n.a, Film-coated tablet, TIXTELLER - 550 MG COMPRESSE RIVESTITE CON FILM 14 COMPRESSE IN BLISTER PVC/PE/PVDC/AL | UMBERTO I - POLICLINICO DI ROMA, ALFA WASSERMANN S.p.A | PATIENTS WITH CIRRHOSIS CHILD PUGH B or C Classes PAZIENTI AFFETTI DA CIRROSI EPATICA CLASSE CHILD-PUGH B or C, ADVANCED CHRONIC LIVER DISEASE MALATTIA EPATICA CRONICA AVANZATA, Diseases [C] - Digestive System Diseases [C06] | | | | |
2018-001891-39: Antibiotic treatment (Rifaxamin) of a chronic inflammatory diarrhoeal disease (Collagenous Colitis) |
|
|
| Ongoing | 3 | 48 | Europe | Xifaxan, Coated tablet, Xifaxan | XiCoCo study group, Norgine, Forskningsfonden Hospitalenhed Midt | Collagenous Colitis, Collagenous colitis is a chronic inflammatory diarrhoeal disease. The hypothesis is that supplemental treatment wit Xifaxan can lower the risk of relapse after discontinuation of standard treatment., Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT04159870: Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis |
|
|
| Active, not recruiting | 3 | 322 | Europe | Rifaximin, Norfloxacin | Ospedali Riuniti di Foggia | Spontaneous Bacterial Peritonitis | 11/21 | 12/21 | | |
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites |
|
|
| Completed | 3 | 160 | Europe | Rifaximin, Placebo | Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA | Cirrhosis, Ascites, Peritonitis | 06/22 | 03/23 | | |
NCT01345175: Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer |
|
|
| Completed | 3 | 69 | US | Rifaximin, At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving, metronidazole in a followup, single arm study in which all patients receive the antibiotic., Patients who wish to participate will be mailed a drug prescription for a 3 week course of, metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and, posttreatment BFI scores will be collected and analyzed for change in bowel function as, was done in the initial Phase III study., Placebo, At 1 - 24 months after completion of the phase III portion of the trial,, patients will be contacted by phone and given the option of receiving, metronidazole in a followup, single arm study in which all patients receive, the antibiotic. Patients who wish to participate will be mailed a drug, prescription for a 3 week course of metronidazole 500mgs tid as well as the, BFI forms and stool diary. Pretreatment and post treatment BFI scores will be, collected and analyzed for change in bowel function as was done in the initial, Phase III study. | Memorial Sloan Kettering Cancer Center | Rectal Cancer | 03/23 | 03/23 | | |
NCT04244877: Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility |
|
|
| Withdrawn | 3 | 20 | NA | Rifaximin, Xifaxan | MetroHealth Medical Center | Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth, Gastrointestinal Motility Disorder | 05/23 | 12/23 | | |
NCT06234046: Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin |
|
|
| Completed | 3 | 80 | RoW | Rifaximin 550Mg Tab, gastrobiotic, Ciprofloxacin 750 MG, Cipro, ascitic fluid sample, aspiration of ascitic fluid | Ain Shams University | Spontaneous Bacterial Peritonitis | 11/23 | 12/23 | | |
NCT02120196: Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis |
|
|
| Recruiting | 3 | 100 | RoW | Rifaximin, Gastrobiotic, Trencedia, Norfloxacin, Epinor | Sherief Abd-Elsalam, Tanta University | Spontaneous Bacterial Peritonitis, Ascites, Liver Cirrhosis | 12/23 | 12/23 | | |
NCT05754996: Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy |
|
|
| Recruiting | 3 | 102 | RoW | Nifuroxazide, Lactulose, Rifaximin 550Mg Tab | Cairo University | Hepatic Encephalopathy | 12/24 | 12/24 | | |
RED-C-3131, NCT05071716: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis |
|
|
| Active, not recruiting | 3 | 524 | Canada, US, RoW | Rifaximin SSD, Placebo | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 09/25 | 09/25 | | |
RED-C-3132, NCT05297448: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis |
|
|
| Active, not recruiting | 3 | 466 | Europe, Canada, US, RoW | Rifaximin SSD, Placebo | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 01/26 | 01/26 | | |
NCT04161053: Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy |
|
|
| Recruiting | 3 | 60 | RoW | Rifaximin, Gastrobiotic, Trencedia, Nitazoxanide, Nanazoxid | Tanta University | Hepatic Encephalopathy | 11/28 | 12/28 | | |
NCT03962283: Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users |
|
|
| Recruiting | 2/3 | 78 | RoW | Rifaximin, Placebo oral tablet | Chinese University of Hong Kong, Beijing Friendship Hospital | Small Bowel Disease, Rifaximin | 06/22 | 06/23 | | |
NCT02651740: Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea |
|
|
| Recruiting | 2/3 | 10 | RoW | Rifaximin, Brand name: XIFAXAN; Production company: SALIX PHARMS, Fecal microbiota transplantation | Shanghai Zhongshan Hospital | Irritable Bowel Syndrome | 07/23 | 12/23 | | |
NCT05408910: Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis |
|
|
| Not yet recruiting | 2/3 | 100 | US | Rifaximin 550 MG Oral Tablet [XIFAXAN], Placebo | Wake Forest University Health Sciences, Nationwide Children's Hospital, University of Minnesota, University of Texas Southwestern Medical Center | Cystic Fibrosis, Abdominal Pain, Small Bowel Disease | 11/24 | 11/24 | | |
NCT05587036: Effects of Rifaximin on Gut Microbiota and Emotion |
|
|
| Recruiting | 2/3 | 60 | Europe | Rifaximin, Targaxan, Placebo | Universitaire Ziekenhuizen KU Leuven | Healthy Volunteers, Stress, Fear | 11/24 | 12/24 | | |
NCT03613545: Fecal Microbiota Transplantation for Irritable Bowel Syndrome |
|
|
| Recruiting | 2/3 | 120 | RoW | fecal microbiota transplantation, Infusion of sham, probiotics, antibiotics or antidepressants, rifaximin, Clostridium butyricum TO-A | Guangzhou First People's Hospital | Irritable Bowel Syndrome, Fecal Microbiota Transplantation | 12/28 | 12/30 | | |
ACTRN12612001026819: Bacterial translocation and amelioration of liver cell damage in response to treatment with propranolol, with or without rifaximin, in patients with cirrhosis and portal hypertension |
|
|
| Not yet recruiting | 2 | 50 | | | Professor Stephen Riordan, Professor Stephen Riordan | Cirrhosis and portal hypertension | | | | |
| Ongoing | 2 | 150 | Europe | Xifaxan, Precosa, Precosa, Coated tablet, Capsule, Xifaxan, Precosa | Oslo University Hospital, Oslo University Hospital | Heart failure, Adult patients with systolic heart failure who fulfill the inclusion and exclusion criteria will be invited to participate in the study, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04302402: Multi-dimensional Clinical and Pathophysiological Profiles of Patients With Functional Dyspepsia and Effect of Gut Microbiota Manipulation Using Rifaximin for Its Treatment |
|
|
| Not yet recruiting | 2 | 132 | RoW | Rifaximin, Normix, Placebo | Sanjay Gandhi Postgraduate Institute of Medical Sciences, Institute of Advanced Study in Science and Technology | Dyspepsia | 03/21 | 03/23 | | |
NCT04118699: Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial |
|
|
| Active, not recruiting | 2 | 12 | Japan | Rifaximin oral tablet, L-105, Placebo oral tablet | Yokohama City University, ASKA Pharmaceutical Co., Ltd. | Chronic Intestinal Pseudo-obstruction | 11/21 | 01/22 | | |
NCT04043897: Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis |
|
|
| Recruiting | 2 | 10 | US | Rifaximin 550mg | Eugene F Yen, MD | Microscopic Colitis | 12/21 | 12/21 | | |
| Not yet recruiting | 2 | 60 | Europe | Film-coated tablet, TARGAXAN | KU Leuven, European Research Council (ERC) | Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test whether rifaximin administration has an effect on sensitivity to psychosocial stress, fear learning, and mood, Experimental study with healthy participants from the general population. We will test if rifaximin administration has an effect on sensitivity to psychosocial stress, fear learning, and mood., Psychiatry and Psychology [F] - Psychological processes [F02] | | | | |
NCI-2020-00332, NCT04249622: Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer |
|
|
| Active, not recruiting | 2 | 20 | US | Best Practice, standard of care, standard therapy, Questionnaire Administration, Rifaximin, Xifaxan | Mayo Clinic, National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8 | 12/22 | 12/24 | | |
NCT05098028: Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease |
|
|
| Completed | 2 | 44 | Canada, US, RoW | Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER, High Dose Rifaximin DER, Placebo | Bausch Health Americas, Inc. | Sickle Cell Disease | 09/23 | 09/23 | | |
NCT04254549: Rifaximin in Patients With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 40 | US | Rifaximin, TD-1473, Placebo | Mayo Clinic | Crohn Disease, Diabetic Gastroparesis | 12/24 | 12/24 | | |
NCT05502913: Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Antibiotics, Rifaximin, FMT (Fecal Microbiota Transplantation) | Soroka University Medical Center, Biotax Labs LTD, Israel Cancer Association | Metastatic Lung Cancer | 06/25 | 06/28 | | |
NCT06058572: Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia |
|
|
| Not yet recruiting | 2 | 166 | NA | Rifaximin with allogeneic stem cell transplant, Allogeneic stem cell transplant | Tata Memorial Centre | Acute Leukemia | 10/26 | 10/26 | | |
NCT04557215: Efficacy and Safety of Rifaximin With NAC in IBS-D |
|
|
| Completed | 1/2 | 45 | US | Rifaximin, xifaxan, N-acetylcysteine, NAC, Placebo | Cedars-Sinai Medical Center, Bausch Health Ireland Limited | Irritable Bowel Syndrome With Diarrhea | 08/21 | 10/22 | | |
NCT05453916: Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation |
|
|
| Recruiting | 1/2 | 84 | RoW | Nitazoxanide 500Mg Oral Tablet, Rifaximin 550Mg Tab | Sadat City University | Irritable Bowel Syndrome With Diarrhea | 07/24 | 12/24 | | |
| Active, not recruiting | 1/2 | 60 | Europe | Fecal Microbiota Transfer provided by Human Biome Institute, Pretreatment with rifaximin 3x 400 mg PO for 7 days, Assessment of levodopa/benserazide 100+25 mg tablet absorption before and 90 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention- Area under the curve (AUC), Cmax, Assessment in clinical scales | Medical University of Warsaw, Human Biome Institute S.A. | Parkinson Disease | 10/23 | 12/24 | | |
| Suspended | 1/2 | 86 | US | Rifaximin, Placebo | University of California, San Francisco, Nova Southeastern University, Gateway Institute for Brain Research | Parkinson Disease | 06/25 | 06/25 | | |
NCT06518850: Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension |
|
|
| Not yet recruiting | 1/2 | 30 | NA | Rifaximin | Peking Union Medical College Hospital, Navy General Hospital, Beijing, Air Force Military Medical University, China, Beijing Tongren Hospital, Beijing Friendship Hospital, Beijing Chao Yang Hospital, Beijing Tiantan Hospital, The Luhe Teaching Hospital of the Capital Medical University, China-Japan Friendship Hospital, Beijing Aerospace General Hospital, Beijing Jishuitan Hospital, Peking University Third Hospital | Small Intestine Bacterial Overgrowth | 12/24 | 12/25 | | |
ChiCTR2200058811: Establishment of a Nomogram model to predict portal vein thrombosis in cirrhosis and clinical study of its intervention |
|
|
| Not yet recruiting | 1 | 200 | | Rifaximin (standard dose 200mg/ time, three times a day, for 14 days) + conservative treatment according to the condition ;Conservative treatment according to the condition | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, None | Cirrhosis of the liver | | | | |
NCT06298409: Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® |
|
|
| Recruiting | 1 | 34 | US | CapScan collection capsule | Envivo Bio Inc | Small Intestinal Bacterial Overgrowth | 06/25 | 07/25 | | |
NCT03820817: Rifaximin in Patients With Monoclonal Gammopathy |
|
|
| Recruiting | 1 | 48 | US | Rifaximin, Xifaxan | Emory University, The Leukemia and Lymphoma Society | IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy, Light Chain Deposition Disease, Monoclonal Gammopathy, Smoldering Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia, Gammopathy, Monoclonal, Gammopathy Igg | 11/25 | 11/25 | | |
NCT05159427: Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers |
|
|
| Recruiting | 1 | 40 | US | Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide, Stable Isotope Glipizide | University of Michigan, Food and Drug Administration (FDA) | Human Gastrointestinal Physiology Data | 09/26 | 09/26 | | |
| Recruiting | 1 | 124 | RoW | Rifaximin 200 mg, Standard Treatment without Rifaximin | Sun Yat-sen University | Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV, Hepatitis B, Rifaximin, Effect of Drug | 07/25 | 10/25 | | |
| Completed | N/A | 160 | | Rifaximin ;Placebo ;None | Peking University Third Hospital; Peking University Third Hospital, UMHS-PKHSC Joint Institute Discovery Award | Irritable bowel syndrome | | | | |
ChiCTR-IOR-16009619: Evidence-based treatment and prevention of upper gastrointestinal hemorrhage induced by portal hypertension |
|
|
| Not yet recruiting | N/A | 600 | | HVPG ;rifaximin ;placebo ;Devascularization ;bypass | Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Shenkang upgrading project of Major disease's clinical skills | Portal hypertension | | | | |
ChiCTR1900028398: Study for Optimized Antiviral Therapy and Evaluation of Clinical Hard Endpoint Events in Patients with Different Types of Decompensated Hepatitis B Cirrhosis |
|
|
| Not yet recruiting | N/A | 480 | | Entecavir monotherapy ;Entecavir combined with alpha 1 thymosin ;Entecavir and rifaximin 6 months ;Entecavir and rifaximin 12 months | Beijing You'an Hospital, Capital Medical University; Beijing You'an Hospital, Capital Medical University, National Science and Technology Major Project Office | Decompensated Hepatitis B Cirrhosis | | | | |
ChiCTR1900023843: Effects of intestinal flora distribution and mucosal structure on pediatric liver transplantation with biliary atresia |
|
|
| Not yet recruiting | N/A | 40 | | No ;probiotics ;Rifaximin | Tianjin First Center Hospital; Tianjin First Center Hospital, Tianjin Clinical Research Center for Organ Transplantation | Biliary Atresia | | | | |
ChiCTR2000040960: Comparison of probiotics and rifaximin in the prevention and treatment of minimal hepatic encephalopathy and their effects on intestinal flora in patients with liver cirrhosis |
|
|
| Recruiting | N/A | 60 | | 3 bid capsules of Bifidobacterium Triple Live bacteria ;Rifaximin0.6g, bid ;Lactulose (Adjust freely according to the number of stools) | Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University; Level of the institution：, The science and technology Department of Anhui Province | minimal hepatic encephalopathy | | | | |
ChiCTR1800018070: Clinical study of rehoci combined with long-acting octreotide in reducing the risk of rebleeding in patients with cirrhosis and portal hypertension |
|
|
| Not yet recruiting | N/A | 80 | | placebo ;rifaximin ;long acting octreotide ;rifaximin+long acting octreotide | Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self financing | portal hypertension | | | | |
ChiCTR2000034943: Study on the correlation between small intestinal bacterial overgrowth and gastroesophageal reflux disease |
|
|
| Not yet recruiting | N/A | 180 | | rifaximin ;Nil | The PLA Rocket Force Characteristic Medical Center; The PLA Rocket Force Characteristic Medical Center, Beijing Municipal Science & Technology Commission | gastroesophageal reflux disease | | | | |
ChiCTR2100046043: study on the clinical characteristics, intestinal microbial composition and standardized diagnosis and treatment of intestinal bacterial overgrowth in elderly military health care population |
|
|
| Recruiting | N/A | 150 | | probiotics ;metronidazole ;rifaximin | PLA General Hospital; PLA General Hospital, Health care special scientific foundation, No. 17BJZ46 | small intestinal bacterial overgrowth | | | | |
ChiCTR2100046346: A single-center, randomized, single-blind clinical study to evaluate the efficacy and safety of rifaximin in the treatment of primary biliary cholangitis |
|
|
| Recruiting | N/A | 60 | | Ursodeoxycholic acid ;UDCA and rifaximin | Xiangya Hospital of Central South University; Xiangya Hospital, National Natural Science Foundation of China | primary biliary cholangitis | | | | |
ChiCTR2100049277: Application of Hydrogen and methane-based breath testing in Diagnosis and Treatment of Digestive System Diseases |
|
|
| Recruiting | N/A | 184 | | Rifaximin combined Live combined B.Subtilis and E.Faecium Enteric-coated capsules ;Rifaximin combined Live combined B.Subtilis and E.Faecium Enteric-coated capsules ;Rifaximin combined Live combined B.Subtilis and E.Faecium Enteric-coated capsules ;Rifaximin combined Live combined B.Subtilis and E.Faecium Enteric-coated capsules ;Rifaximin combined Live combined B.Subtilis and E.Faecium Enteric-coated capsules ;Rifaximin combined Live combined B.Subtilis and E.Faecium Enteric-coated capsules ;Rifaximin combined Live combined B.Subtilis and E.Faecium Enteric-coated capsules ;Rifaximin combined Live combined B.Subtilis and E.Faecium Enteric-coated capsules | the Sixth Medical Center of PLA General Hospital; The Sixth Medical Center of PLA General Hospital, Beijing Municipal Commission of Health | small intestinal bacterial overgrowth | | | | |
NCT06223685: The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin |
|
|
| Recruiting | N/A | 125 | Europe | Rifaximin 200 MG, Xifaxan, Probiotic | Pomeranian Medical University Szczecin | Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth, SIBO | 08/24 | 04/25 | | |
ChiCTR2200057554: A Randomised Controlled Clinical Study of Berberine and Rifaximin for Small Intestinal Bacterial Overgrowth |
|
|
| Not yet recruiting | N/A | 180 | | Berberine hydrochloride tablets, 400mg, twice a day for 14d ;Rifaximin tablets, 400mg, twice a day for 14d | Peking University Third Hospital; Peking University Third Hospital, National Key Research and Development Program of China (2019YFA0905604) | Small intestinal bacterial overgrowth | | | | |
NCT06199843: Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial) |
|
|
| Not yet recruiting | N/A | 280 | RoW | Rifaximin, Norfloxacin | Institute of Liver and Biliary Sciences, India | Spontaneous Bacterial Peritonitis | 12/24 | 12/24 | | |
ChiCTR2100049794: The effect of prophylactic antibiotic rifaximin in acute pancreatitis on infection and related clinical prognosis: prospective, randomized, open trial study |
|
|
| Not yet recruiting | N/A | 60 | | Oral Rifaximin ;None | The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, National Natural Science Foundation of China | acute pancreatitis | | | | |
NCT04910815: Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting. |
|
|
| Recruiting | N/A | 150 | RoW | Atmo Gas Capsule, Glucose Breath Test, Fructoolifosaccharides (FOS) Breath Test, Jejunal Aspiration and culture, Rifaximin, Placebo | Atmo Biosciences Pty Ltd | Small Intestinal Bacterial Overgrowth | 06/24 | 08/24 | | |
HERB, NCT06538077: BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE |
|
|
| Not yet recruiting | N/A | 336 | RoW | Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose, Placebo for BCAA, Placebo for Rifaximin 550mg | Post Graduate Institute of Medical Education and Research, Chandigarh, Indian Council of Medical Research | Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy | 08/25 | 08/27 | | |
| Not yet recruiting | N/A | 174 | RoW | Human albumin infusion at a modified dosage, AlbuRx, Human albumin infusion at a routine dosage, Lactulose, Duphalac, Rifaximin, Xifaxan, Ornithine Aspartate, Branched-Chain Amino Acids, Compound amino acid injection, Arginine, Arginine Hydrochloride Injection, plasma exchange | General Hospital of Shenyang Military Region | Overt Hepatic Encephalopathy | 06/27 | 06/27 | | |
ChiCTR2200055455: Preliminary experimental study of rifaximin in the treatment of metabolic-related fatty liver disease |
|
|
| Recruiting | N/A | 80 | | Rifaximin treatment ;None | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Scientific research project of Shanghai Municipal Commission of Health | Metabolic Associated Fatty Liver Disease | | | | |
ChiCTR2300067687: Efficacy and Safety of Rifaximin-metformin combination in Treating Metabolic Associated Fatty Liver Disease (MAFLD): A Pilot Clinical Trial |
|
|
| Not yet recruiting | N/A | 120 | | Rifaximin treatment ;Metformin treatment ;Rifaximin-metformin treatment ;Control group | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Scientific research project of Shanghai Municipal Commission of Health | Metabolic Associated Fatty Liver Disease | | | | |
ChiCTR2400081439: Prospective single-center randomized controlled study of oral Rifaximin for prevention of cholangitis after ERCP drainage in patients with malignant biliary obstruction |
|
|
| Not yet recruiting | N/A | 58 | | Rifaximin was taken orally 3 times a day, 1 capsule each time; No special intervention | Affiliated Drum Tower Hospital of Nanjing University Medical School; Affiliated Drum Tower Hospital of Nanjing University Medical School, self-raised | Malignant biliary obstruction | | | | |
RPPCLC, NCT05863364: Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis |
|
|
| Recruiting | N/A | 150 | RoW | Low-dose of Rifaximin, Low-dose of Xifaxan, Conventional dose of Rifaximin, Conventional dose of Xifaxan | Xin Zeng | Decompensated Cirrhosis | 12/25 | 12/25 | | |